Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

"Estudi de la suceptibilitat genètica com a predictor de la pèrdua de pes i la resolució de les comorbiditats associades a l'obesitat després de cirurgía bariàtrica"

IP: Rafael Simó Canonge
Collaborators: Gemma Cuberas Borros
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 32160
Reference: SLT002/16/00497
Duration: 01/01/2017 - 31/12/2019

Grups de recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2017SGR01144
Duration: 12/04/2019 - 30/09/2021

Administración tópica de agonistas del receptor de GLP-1: una nueva estrategia para el tratamiento de la retinopatía deiabética

IP: Rafael Simó Canonge
Collaborators: Patricia Bogdanov Baruj
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 266200
Reference: SAF2016-77784-R
Duration: 30/12/2016 - 29/12/2019

Related news

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.

The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.

The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.

Related professionals

Herimar Meneses Fuenmayor

Herimar Meneses Fuenmayor

Gestió i Administració
Quality, Processes and Document Management Unit
Digital Transformation Directorate
Read more
Andres Rodrigo Parra  Rojas

Andres Rodrigo Parra Rojas

Predoctoral researcher
Infectious Diseases
Read more
Novica Nikolic

Novica Nikolic

Research assistant
Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)
Read more
María Viñas I Casas

María Viñas I Casas

Predoctoral researcher
Protein kinases in cancer research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.